No long-term animal studies have been done to determine whether diflorasone could have carcinogenic properties.
Women who are breastfeeding their newborns should probably not use diflorasone since corticosteroids have been known to appear in breast milk and cause negative effects in a newborn, such as inhibited growth, but little data is available regarding whether topical corticosteroids like diflorasone would be present in great enough quantities to cause harm to an infant.
FDA APPROVES TARO'S ANDA FOR DIFLORASONE DIACETATE CREAM.(Taro Pharmaceuticals Inc.)(Brief Article)(Statistical Data Included)
Jun 01, 2000; Taro Pharmaceuticals Inc., Canadian subsidiary of Taro Pharmaceutical Industries Ltd., has received notification from the U.S....